North Carolina House Bill H163

North Carolina 2025-2026 Regular Session

• Introduced: 2/21/25
• Refer: 2/24/25
• Report Pass: 4/1/25
• Refer: 4/1/25
• Report Pass: 4/15/25
• Refer: 4/15/25

Caption

Pharmacy Benefits Manager Provisions

Impact

The bill's implementation is expected to enhance transparency within the healthcare system by mandating that PBMs disclose pricing structures and concessions they negotiate with drug manufacturers. By preventing PBMs from imposing excessive or unfair pricing on pharmacies, HB 163 looks to promote fair competition and access to affordable medications for consumers. It significantly amends existing regulations that govern pharmacy services, introducing protective measures that support both pharmacies and consumers against potential exploitation by PBMs.

Summary

House Bill 163 aims to regulate the operations of pharmacy benefits managers (PBMs) within North Carolina, focusing primarily on the issue of spread pricing—that is, the difference between what PBMs charge insurers for prescription drugs and what they reimburse pharmacies. The legislation establishes uniform standards regarding the treatment of specialty pharmacies and reinforces patients' right to select their pharmacies of choice under health benefit plans. It also outlines measures to protect pharmacies during audits and places restrictions on the fees that PBMs can charge pharmacies, ensuring a more equitable pricing structure for medication dispensation.

Sentiment

Feedback from stakeholders has been largely supportive among pharmacies and patient advocacy groups, recognizing the need for reforms that counter the monopolistic practices of some PBMs. However, there is concern expressed by certain insurance representatives about potential increases in drug costs resulting from stricter regulations on PBM operations. The legislation reflects an ongoing tension between ensuring patient access to affordable medications and managing the financial implications for insurers and PBMs.

Contention

While proponents herald the bill as a critical step toward leveling the playing field in the pharmaceutical landscape, opponents warn that it may disrupt existing insurer-pharmacy agreements and pose challenges in negotiating drug pricing going forward. The legislation is set to take effect in phases, with particular sections becoming enforceable in late 2025, allowing for a transitional period for stakeholders to adapt to the new regulatory environment.